The long-term goals of this proposal are to define mechanisms of regulation of hepatic lipase (HL) levels and to determine how genetic variation at the HL gene locus modulates these levels under a variety of physiological and pathological states. HL plays a key role in lipoprotein metabolism by catalyzing the hydrolysis of triglycerides and phospholipids. A high level of HL is associated with two important metabolic risk factors for atherosclerosis: diminished concentrations of plasma high density lipoprotein cholesterol (HDL-C) and an increased prevalence of small, dense low density lipoprotein (LDL) particles. A significant proportion (20-30%) of the total variability in HL activity is explained by the common genetic variation in the regulatory sequences of the HL gene whereby, the variant form was observed to be associated with lower HL and higher HDL2 levels. Gender is another modulating factor since women have, on average, higher levels of HDL2 and lower levels of HL. The underlying hypotheses of this proposal are, first, that one or more of the observed regulatory sequence variants causes diminished HL gene expression which, in turn, results in increased HDL-C levels and expression is regulated by cholesterol and estrogens. Our preliminary in vitro studies indicate that sterols up-regulate and estrogens down-regulate activity of the HL gene promoter, respectively.
The specific aims are to: 1) Determine by association and linkage analysis whether the observed LIPC promoter variants underlie the observed interindividual variation in levels of hepatic lipase activity and HDL2 estrogens and sterols and assess the role of the regulatory sequence variants modulate the relationships between HL levels and gender, menopause status, estrogen replacement therapy and intra-abdominal fat deposits. The results of these studies will provide insights into the molecular genetic bases for interindividual variation in HL activity and the associated plasma lipoprotein profiles. This will open the door for novel pharmaceutical approaches that target modification of the lipoproteins.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL064322-03
Application #
6390628
Study Section
Metabolism Study Section (MET)
Program Officer
Applebaum-Bowden, Deborah
Project Start
1999-09-30
Project End
2003-08-31
Budget Start
2001-09-01
Budget End
2003-08-31
Support Year
3
Fiscal Year
2001
Total Cost
$305,547
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Brunzell, John D; Zambon, Alberto; Deeb, Samir S (2012) The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype. Biochim Biophys Acta 1821:365-72
Lee, Christine G; Carr, Molly C; Murdoch, Susan J et al. (2009) Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study. J Clin Endocrinol Metab 94:1104-10
Purnell, Jonathan Q; Bland, Lisa B; Garzotto, Mark et al. (2006) Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer. J Lipid Res 47:349-55
Rufibach, Laura E; Duncan, Stephen A; Battle, Michele et al. (2006) Transcriptional regulation of the human hepatic lipase (LIPC) gene promoter. J Lipid Res 47:1463-77
Zambon, A; Brown, B G; Deeb, S S et al. (2006) Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease. J Intern Med 259:473-80
Zambon, Alberto; Puato, Massimo; Faggin, Elisabetta et al. (2006) Common hepatic lipase gene promoter variant predicts the degree of neointima formation after carotid endarterectomy: impact of plaque composition and lipoprotein phenotype. Atherosclerosis 185:121-6
Zambon, A; Brown, B G; Hokanson, J E et al. (2006) Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy. J Intern Med 259:401-9
Carr, Molly C; Knopp, Robert H; Brunzell, John D et al. (2005) Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy. Diabetes Care 28:1555-61
Lewis, Gary F; Murdoch, Susan; Uffelman, Kristine et al. (2004) Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone. Diabetes 53:2893-900
Carr, Molly C; Brunzell, John D; Deeb, Samir S (2004) Ethnic differences in hepatic lipase and HDL in Japanese, black, and white Americans: role of central obesity and LIPC polymorphisms. J Lipid Res 45:466-73

Showing the most recent 10 out of 22 publications